Skip to main content

Emerging agents and regimens for cancer therapy 2020

This Journal of Hematology & Oncology collection is the 2020 version of an annual series on emerging agents and regimens for cancer therapy.

The series, which is no longer open for submissions, will include research and review papers on novel agents, first-in-human clinical trials, and regimens for different cancer types.

Articles published in the collection have already gone through the systematic peer review process of the journal.

For published articles in "Emerging agents and regimens for cancer therapy 2019," see here.

New Content Item

  1. Cancer microenvironment is critical for tumorigenesis and cancer progression. The extracellular matrix (ECM) interacts with tumor and stromal cells to promote cancer cells proliferation, migration, invasion, a...

    Authors: Yangfu Jiang, Hongying Zhang, Jiao Wang, Yongliang Liu, Ting Luo and Hui Hua
    Citation: Journal of Hematology & Oncology 2022 15:34
  2. Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F (UBE2F) are the two NEDD8-conjugating enzymes of the neddylation pathway that take part in posttranslational modification and cha...

    Authors: Yi-Chao Zheng, Yan-Jia Guo, Bo Wang, Chong Wang, M. A. A. Mamun, Ya Gao and Hong-Min Liu
    Citation: Journal of Hematology & Oncology 2021 14:57
  3. Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. Allogenei...

    Authors: Hongtao Liu
    Citation: Journal of Hematology & Oncology 2021 14:49
  4. Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic agents and immune checkpoint inhibito...

    Authors: Anwaar Saeed, Robin Park and Weijing Sun
    Citation: Journal of Hematology & Oncology 2021 14:13
  5. Natural killer (NK) cell is a specialized immune effector cell type that plays a critical role in immune activation against abnormal cells. Different from events required for T cell activation, NK cell activat...

    Authors: Sizhe Liu, Vasiliy Galat, Yekaterina Galat4, Yoo Kyung Annie Lee, Derek Wainwright and Jennifer Wu
    Citation: Journal of Hematology & Oncology 2021 14:7
  6. T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas (NHL) that often present at an advanced stage at the time of diagnosis and that most commonly have an aggressive clinical course. ...

    Authors: Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak and Grzegorz K. Przybylski
    Citation: Journal of Hematology & Oncology 2020 13:176
  7. As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and t...

    Authors: Liang Wang, Lin-rong Li and Ken H. Young
    Citation: Journal of Hematology & Oncology 2020 13:175
  8. Cell death escape is one of the most prominent features of tumor cells and closely linked to the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic family member myeloid ...

    Authors: Arnold Bolomsky, Meike Vogler, Murat Cem Köse, Caroline A. Heckman, Grégory Ehx, Heinz Ludwig and Jo Caers
    Citation: Journal of Hematology & Oncology 2020 13:173

    The Correction to this article has been published in Journal of Hematology & Oncology 2021 14:31

  9. Hyperactive signaling of the Janus-Associated Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway is central to the pathogenesis of Philadelphia-chromosome-negative myeloproliferative ...

    Authors: Sangeetha Venugopal and John Mascarenhas
    Citation: Journal of Hematology & Oncology 2020 13:162
  10. The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplant...

    Authors: Yang Yang, Yi Li, Huiyao Gu, Mengmeng Dong and Zhen Cai
    Citation: Journal of Hematology & Oncology 2020 13:150
  11. Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-rib...

    Authors: Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong and Tian Zhang
    Citation: Journal of Hematology & Oncology 2020 13:144
  12. Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous s...

    Authors: Walter Hanel and Narendranath Epperla
    Citation: Journal of Hematology & Oncology 2020 13:79
  13. Recent years have witnessed major advances that have improved outcome of adults with acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual disease has fine-tuned our prognosti...

    Authors: Bachar Samra, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian and Nicholas J. Short
    Citation: Journal of Hematology & Oncology 2020 13:70
  14. Insulin-like growth factors (IGFs) play important roles in mammalian growth, development, aging, and diseases. Aberrant IGFs signaling may lead to malignant transformation and tumor progression, thus providing...

    Authors: Hui Hua, Qingbin Kong, Jie Yin, Jin Zhang and Yangfu Jiang
    Citation: Journal of Hematology & Oncology 2020 13:64
  15. Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for the nuclear-cytoplasmic transport ...

    Authors: Nancy G. Azizian and Yulin Li
    Citation: Journal of Hematology & Oncology 2020 13:61
  16. Cancer stem cells (CSCs) contribute to the initiation, recurrence, and metastasis of cancer; however, there are still no drugs targeting CSCs in clinical application. There are several signaling pathways playi...

    Authors: Yue Yang, Xiaoman Li, Ting Wang, Qianqian Guo, Tao Xi and Lufeng Zheng
    Citation: Journal of Hematology & Oncology 2020 13:60